RedChip Companies will air interviews with Bullfrog AI Holdings, Inc. (Nasdaq:BFRG) and Connect Biopharma Holdings Limited ...

A RECENT study has highlighted key biological and clinical factors linked to resistance to biologic therapies in patients ...

A pioneering study presented today at ESCMID Global 2025 has uncovered the potential of interleukin-6 (IL-6) as a powerful diagnostic biomarker for the early detection of sepsis in high-risk patient ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Hong Kong restaurant group Masterbeef raised $8M in its IPO earlier this week. Shares of the investment research platform Aether also made ...

Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib — a ...

They achieved this by developing sucralfate microneedles (SUC-MN) to deliver an important immunomodulatory protein, interleukin-4 (IL-4), to stimulate the production of growth factors in diabetic ...

This approval is the fourth indication for this dual-acting interleukin-23 inhibitor in the United States ... In the GRAVITI study, Tremfya (400 mg subcutaneous induction at weeks 0, 4, and 8) led to ...

The following is a summary of “CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic ...

Explore the promising results of haematopoietic stem cell transplantation as a treatment for early-onset inflammatory bowel ...